ecrin-mdr-crcClinical2006Intestinal adenocarcinomaColorectal CancerColorectal Neoplasmsmetastatic colorectal adenocarcinomaMetastatic Colorectal AdenocarcinomaColorectal CancerColorectal NeoplasmsIntestinal AdenocarcinomaInterventionalhttps://newmdr.ecrin.org/Study/2035904United StatesItaly12Metastatic colorectal adenocarcinomaEverolimusAnti-EGFR antibodyECRIN MDRCompletedfalseEfficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and ChemotherapyTo assess the safety and efficacy of weekly (70 mg per week) and daily (10 mg per day) everolimus in patients with metastatic colorectal cancer whose cancer has progressed despite prior treatment with targeted therapy and chemotherapy.2006-12-152035904NCT004191592006-003255-20